159 related articles for article (PubMed ID: 12605319)
1. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Winkelmann RR; Yiannias JA; DiCaudo DJ; Trotter SC; Farhey Y; Griffing WL; Martorano LM; Winkelmann JC
Int J Dermatol; 2016 Jan; 55(1):97-100. PubMed ID: 25266415
[No Abstract] [Full Text] [Related]
3. Scleroderma and the taxanes. Is there really a link?
Farrant PB; Mortimer PS; Gore M
Clin Exp Dermatol; 2004 Jul; 29(4):360-2. PubMed ID: 15245529
[TBL] [Abstract][Full Text] [Related]
4. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel.
Konishi Y; Sato H; Sato N; Fujimoto T; Fukuda J; Tanaka T
J Obstet Gynaecol Res; 2010 Jun; 36(3):693-6. PubMed ID: 20598060
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
Seishima M; Izumi T; Kanoh H
Eur J Dermatol; 2000; 10(1):55-8. PubMed ID: 10694301
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
7. Scleroderma induced by paclitaxel.
Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
[No Abstract] [Full Text] [Related]
8. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.
Dasanu CA; Alexandrescu DT
South Med J; 2008 Nov; 101(11):1161-2. PubMed ID: 19088531
[TBL] [Abstract][Full Text] [Related]
9. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer.
Kawakami T; Tsutsumi Y; Soma Y
Arch Dermatol; 2009 Jan; 145(1):97-8. PubMed ID: 19153362
[No Abstract] [Full Text] [Related]
10. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
[TBL] [Abstract][Full Text] [Related]
11. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
13. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
14. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
[TBL] [Abstract][Full Text] [Related]
15. [Scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma].
Eisenbeilss C; Weizel J; Wolff H
J Dtsch Dermatol Ges; 2003 Jun; 1(6):468-70. PubMed ID: 16295141
[TBL] [Abstract][Full Text] [Related]
16. Time to diagnosis in systemic sclerosis: is sex a factor?
Hudson M; Thombs B; Baron M;
Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
[TBL] [Abstract][Full Text] [Related]
17. Extravasation of paclitaxel into breast tissue from central catheter port.
Barutca S; Kadikoylu G; Bolaman Z; Meydan N; Yavasoglu I
Support Care Cancer; 2002 Oct; 10(7):563-5. PubMed ID: 12324812
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
Adachi A; Horikawa T
J Dermatol; 2007 Jul; 34(7):473-6. PubMed ID: 17584326
[TBL] [Abstract][Full Text] [Related]
19. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
